2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1590

Prolonged Antimalarial Treatment Increases the Risk for Severe Brady-Arrhythmias in Systemic Lupus Erythematosus
Abstract Number: 714

Prolonged Antimalarial Treatment Is Associated with Increased Risk for Elevated Myocardial Biomarkers in Systemic Lupus Erythematosus
Abstract Number: 716

Prolonged Exposure to Antiphospholipid Antibodies Is Associated with Endothelial Dysfunction in Patients with Systemic Lupus Erythematosus
Abstract Number: 2568

Prophylactic and Therapeutic Administration of a JAK1-Selective Inhibitor Blocks and Reverses Nephritis and Sialadenitis in NZB/W-F1 Mice
Abstract Number: 1778

Prophylactic Treatment and Incidence of Pneumocystis Jirovecci Pneumonia in Japanese Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Abstract Number: 2045

Prophylaxis of Ischemic Disease in Giant Cell Arteritis Patients: An Application of a “Big Data” Tracking Tool in the Electronic Health Record in an University-Based Medical Center
Abstract Number: 917

Prospective Association of Metabolic Syndrome with Incident Symptomatic Interphalangeal Osteoarthritis but Not Thumb Based or Erosive Hand Osteoarthritis
Abstract Number: 2017

Prospective Study of Bio-Free Remission Maintenance Using Ultrasonography in Rheumatoid Arthritis Patients: 52-Week Result
Abstract Number: 2311

Prospective Validation of the Juvenile Spondyloarthritis Disease Activity Index and Its Comparison with Adult Spondyloarthritis Disease Activity Scores
Abstract Number: 738

Prospective Validation of the Systemic Sclerosis Skin Symptoms Patient-Reported Outcome (SSPRO) in a Phase 2 Trial of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Abstract Number: 1448

Prospective, Intervention, Multicenter, Non-Inferiority Study of Utility of Therapeutic Drug Monitoring with Respect to the Efficacy and Cost of Adalimumab Tapering in Patients with Rheumatic Diseases
Abstract Number: 656

Prostaglandin E2 and Its Receptor Subtype EP4 Are Involved in Ankylosing Spondylitis Disease Progression
Abstract Number: 384

Protection Against Hepatitis B in Immunocompromised Pediatric Rheumatology and Gastroenterology Patients
Abstract Number: 1111

Protective Effect of Allopurinol Use on Kidney Function Among Patients with Gout and Chronic Kidney Disease
Abstract Number: 39

Protein Array Technology Identifies Rituximab-Treated Non-Responder Rheumatoid Arthritis Patients to Generate New Autoantibody Repertoires during Treatment

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].